Skip to content

Jikisha Jain, Kriti Maheshwari, Amandeep Saluja, Kapil Vyas, Kalpana Gupta

Department of Dermatology, Venereology and Leprology, Geetanjali Medical College and Hospital, Udaipur

Background: Immunotherapy has recently emerged as an option to deal with warts while avoiding major drawbacks of destructive modalities as well as preventing recurrence.

Objectives: To compare the efficacy of intralesional injection of Vitamin D3 and MMR vaccine in terms of remission and recurrence and their various side effects in the management of cutaneous warts.

Material and Methods: A total of 60 patients were divided in groups of two. Group A received intralesional MMR vaccine into largest wart, and group B received intralesional vitamin D3 into each lesion with maximum of five warts treated in one session. This was repeated every 3 weeks until complete clearance of all the warts or for a maximum of 3 treatment sessions in both the groups. 6 months follow up was done for any signs of recurrence.

Results: In group A (MMR group) 80% patients showed complete response, 10% showed partial response, 3.3% showed poor response and 6.7 % patients showed no response at all whereas in group B (Vitamin D3), complete response was seen in 70% patients, partial response in 16.7%, poor response in 6.7% and no response in 6.7% patients. There was no significant difference between the two groups regarding the response rate. Only 2 patients in group A and 5 patients in group B showed recurrence of warts groups after 6 month-follow up period.

Conclusions: Both the modalities i.e. intralesional injection MMR and vitamin D3 are effective with good cure rates, excellent safety profile and are cost-effective. They can be considered as first line therapy in management of all cutaneous warts.

Keywords: MMR, immunotherapy, vitamin D, warts

Creative Commons Licence
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Play Video